What is the price target for NZM2 stock?
24 analysts have analysed NZM2.DE and the average price target is 63.75 EUR. This implies a price increase of 24.03% is expected in the next year compared to the current price of 51.4.

FRA:NZM2 • DK0060336014
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NOVONESIS (NOVOZYMES) B (NZM2.DE).
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.396B 1.93% | 3.834B 59.98% | 4.158B 8.45% | 4.479B 7.73% | 4.804B 7.26% | 5.14B 6.99% | 5.453B 6.09% | 5.792B 6.22% | 6.225B 7.48% | 6.544B 5.12% | 6.889B 5.27% | |
| EBITDA YoY % growth | 783.568M -1.52% | 1.256B 60.34% | 1.502B 19.52% | 1.68B 11.88% | 1.83B 8.93% | 1.981B 8.25% | 2.105B 6.26% | 2.258B 7.27% | 2.433B 7.75% | 2.564B 5.38% | 2.699B 5.27% | |
| EBIT YoY % growth | 597.616M 0.14% | 659M 10.27% | 904.7M 37.28% | 1.11B 22.69% | 1.245B 12.16% | 1.394B 11.97% | 1.36B -2.44% | 1.486B 9.26% | 1.69B 13.73% | 1.797B 6.33% | 1.906B 6.07% | |
| Operating Margin | 24.94% | 17.19% | 21.76% | 24.78% | 25.92% | 27.12% | 24.94% | 25.66% | 27.15% | 27.46% | 27.67% | |
| EPS YoY % growth | 1.46 -17.70% | N/A -10.56% | 1.88 43.90% | 2.04 8.49% | 2.26 10.73% | 2.49 10.19% | 2.60 4.59% | 2.82 8.24% | 3.17 12.53% | 3.35 5.75% | 3.54 5.74% |
All data in EUR
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 0.56 33.95% | 0.54 15.18% | 0.57 5.68% | 0.54 20.30% |
| Revenue Q2Q % growth | 1.065B -1.17% | 1.073B 5.35% | 1.133B 6.39% | 1.097B 10.07% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A |
All data in EUR
24 analysts have analysed NZM2.DE and the average price target is 63.75 EUR. This implies a price increase of 24.03% is expected in the next year compared to the current price of 51.4.
NOVONESIS (NOVOZYMES) B (NZM2.DE) will report earnings on 2026-05-05.
The consensus EPS estimate for the next earnings of NOVONESIS (NOVOZYMES) B (NZM2.DE) is 0.56 EUR and the consensus revenue estimate is 1.06B EUR.
The consensus rating for NOVONESIS (NOVOZYMES) B (NZM2.DE) is 79.1667 / 100 . This indicates that analysts generally have a positive outlook on the stock.